Literature DB >> 22505641

Chronic hypoxia induces right heart failure in caveolin-1-/- mice.

J Agustin Cruz1, Eileen M Bauer, Andres I Rodriguez, Archana Gangopadhyay, Nabil S Zeineh, Yinna Wang, Sruti Shiva, Hunter C Champion, Philip M Bauer.   

Abstract

Caveolin-1 (Cav-1)-/- mice develop mild pulmonary hypertension as they age. In this study, we sought to determine the effect of chronic hypoxia, an established model of pulmonary hypertension, on young Cav-1-/- mice with no measurable signs of pulmonary hypertension. Exposure of Cav-1-/- mice to chronic hypoxia resulted in an initial rise in right ventricular (RV) systolic pressure (RVSP) similar to wild-type (WT) mice. By three weeks RVSP decreased in the Cav-1-/- mice, whereas it was maintained in WT mice. The drop in RVSP in Cav-1-/- mice was accompanied by decreased cardiac output, increased RV hypertrophy, RV interstitial fibrosis, decreased RV sarco(endo)plasmic reticulum Ca(2+)-ATPase 2a mRNA and decreased RV function compared with WT mice. Importantly, minimal differences were noted in pulmonary vascular remodeling between WT and Cav-1-/- mice, and left ventricular function was normal in hypoxic Cav-1-/- mice. Mechanistically, increased endothelial nitric oxide synthase uncoupling and increased tyrosine nitration of protein kinase G were detected in the RV of Cav-1-/- mice. These hemodynamic, histological, and molecular changes were prevented in Cav-1-/- mice expressing an endothelial-specific Cav-1 transgene or by nitric oxide synthase inhibition. These data suggest that, in Cav-1-/- mice, increased oxidative/nitrosative stress due to endothelial nitric oxide synthase uncoupling modifies the response of the RV to pressure overload, accelerating the deterioration of RV function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505641      PMCID: PMC3378264          DOI: 10.1152/ajpheart.01140.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  32 in total

Review 1.  Pulmonary complications of sickle cell disease.

Authors:  Mark T Gladwin; Elliott Vichinsky
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

Review 2.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.

Authors:  Harm J Bogaard; Kohtaro Abe; Anton Vonk Noordegraaf; Norbert F Voelkel
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

3.  Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

Authors:  S C Mathai; M Bueso; L K Hummers; D Boyce; N Lechtzin; J Le Pavec; A Campo; H C Champion; T Housten; P R Forfia; A L Zaiman; F M Wigley; R E Girgis; P M Hassoun
Journal:  Eur Respir J       Date:  2009-07-30       Impact factor: 16.671

4.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

5.  HO-1 and CO decrease platelet-derived growth factor-induced vascular smooth muscle cell migration via inhibition of Nox1.

Authors:  Andres I Rodriguez; Archana Gangopadhyay; Eric E Kelley; Patrick J Pagano; Brian S Zuckerbraun; Philip M Bauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-29       Impact factor: 8.311

6.  Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration.

Authors:  You-Yang Zhao; Yidan D Zhao; Muhammad K Mirza; Julia H Huang; Hari-Hara S K Potula; Steven M Vogel; Viktor Brovkovych; Jason X-J Yuan; John Wharton; Asrar B Malik
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

7.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.

Authors:  Eiki Takimoto; Norimichi Koitabashi; Steven Hsu; Elizabeth A Ketner; Manling Zhang; Takahiro Nagayama; Djahida Bedja; Kathleen L Gabrielson; Robert Blanton; David P Siderovski; Michael E Mendelsohn; David A Kass
Journal:  J Clin Invest       Date:  2009-01-05       Impact factor: 14.808

8.  Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice.

Authors:  Carsten Wunderlich; Alexander Schmeisser; Christian Heerwagen; Bernd Ebner; Kristin Schober; Ruediger C Braun-Dullaeus; Carsten Schwencke; Michael Kasper; Henning Morawietz; Ruth H Strasser
Journal:  Pulm Pharmacol Ther       Date:  2007-12-08       Impact factor: 3.410

9.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

10.  Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs.

Authors:  Martina Krüger; Sebastian Kötter; Anika Grützner; Patrick Lang; Christian Andresen; Margaret M Redfield; Elke Butt; Cris G dos Remedios; Wolfgang A Linke
Journal:  Circ Res       Date:  2008-11-20       Impact factor: 17.367

View more
  20 in total

1.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

2.  Protective effects of astragaloside IV against hypoxic pulmonary hypertension.

Authors:  Xiaozheng Zhang; Jun Chen; Pan Xu; Xin Tian
Journal:  Medchemcomm       Date:  2018-09-04       Impact factor: 3.597

3.  Bone marrow transplantation prevents right ventricle disease in the caveolin-1-deficient mouse model of pulmonary hypertension.

Authors:  Kewal Asosingh; Nicholas Wanner; Kelly Weiss; Kimberly Queisser; Liya Gebreab; Biruk Kassa; Eric Stuehr; Brian Graham; Serpil Erzurum
Journal:  Blood Adv       Date:  2017-03-17

4.  Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α.

Authors:  Molly K Ball; Gregory B Waypa; Paul T Mungai; Jacqueline M Nielsen; Lyubov Czech; V Joseph Dudley; Lauren Beussink; Robert W Dettman; Sara K Berkelhamer; Robin H Steinhorn; Sanjiv J Shah; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

5.  Blood outgrowth endothelial cells overexpressing eNOS mitigate pulmonary hypertension in rats: a unique carrier cell enabling autologous cell-based gene therapy.

Authors:  Arif Somani; Sethu L Nair; Liming C Milbauer; Guangshuo Zhu; Suchitra Sajja; Anna Solovey; Yingjie Chen; Robert P Hebbel
Journal:  Transl Res       Date:  2019-04-24       Impact factor: 7.012

6.  Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury.

Authors:  Feng Wu; William S Szczepaniak; Sruti Shiva; Huanbo Liu; Yinna Wang; Ling Wang; Ying Wang; Eric E Kelley; Alex F Chen; Mark T Gladwin; Bryan J McVerry
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-17       Impact factor: 5.464

7.  Nitration of tyrosine 247 inhibits protein kinase G-1α activity by attenuating cyclic guanosine monophosphate binding.

Authors:  Saurabh Aggarwal; Christine M Gross; Ruslan Rafikov; Sanjiv Kumar; Jeffrey R Fineman; Britta Ludewig; Danny Jonigk; Stephen M Black
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

8.  Nitrosation-dependent caveolin 1 phosphorylation, ubiquitination, and degradation and its association with idiopathic pulmonary arterial hypertension.

Authors:  Farnaz R Bakhshi; Mao Mao; Ayesha N Shajahan; Tobias Piegeler; Zhenlong Chen; Olga Chernaya; Tiffany Sharma; W Mark Elliott; Robert Szulcek; Harm Jan Bogaard; Suzy Comhair; Serpil Erzurum; Geerten P van Nieuw Amerongen; Marcelo G Bonini; Richard D Minshall
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

9.  Caveolins: targeting pro-survival signaling in the heart and brain.

Authors:  Creed M Stary; Yasuo M Tsutsumi; Piyush M Patel; Brian P Head; Hemal H Patel; David M Roth
Journal:  Front Physiol       Date:  2012-10-05       Impact factor: 4.566

10.  Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells.

Authors:  Ruslan Rafikov; Xutong Sun; Olga Rafikova; Mary Louise Meadows; Ankit A Desai; Zain Khalpey; Jason X-J Yuan; Jeffrey R Fineman; Stephen M Black
Journal:  Redox Biol       Date:  2015-07-31       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.